Faivre-Finn, C. Et Al. 2021. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.5 , 860-867.

Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., ... Spigel, D. R.(2021). Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.5, 860-867.

Faivre-Finn, Corinne Et Al. "Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.5, 860-867, 2021

Faivre-Finn, Corinne Et Al. "Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.5, pp.860-867, 2021

Faivre-Finn, C. Et Al. (2021) . "Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.5, pp.860-867.

@article{article, author={Corinne Faivre-Finn Et Al. }, title={Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2021, pages={860-867} }